Drug intelligence / Profile preview

SAK2001

Development stage: Unknown
Lead developer: Huiyu Kangcheng
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SAK2001 is an investigational drug developed by Huiyu Kangcheng (Zhejiang) Pharmaceutical Technology. It is currently in Phase 1 clinical trials for the treatment of advanced solid tumors. The primary objectives of ongoing studies are to evaluate the safety, tolerability, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of SAK2001 in humans. Secondary objectives include assessment of pharmacokinetic characteristics and preliminary anti-tumor efficacy. The mechanism of action involves targeting PD-1, suggesting that SAK2001 functions as an immune checkpoint inhibitor aimed at enhancing anti-tumor immune responses[1][3][5].

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on SAK2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAK2001.

Explore the full profile